NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis
Authors
Keywords
-
Journal
Science Translational Medicine
Volume 8, Issue 334, Pages 334ra51-334ra51
Publisher
American Association for the Advancement of Science (AAAS)
Online
2016-04-14
DOI
10.1126/scitranslmed.aad6095
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Curcumin Derivative That Inhibits Vinyl Carbamate-Induced Lung Carcinogenesis via Activation of the Nrf2 Protective Response
- (2015) Tao Shen et al. ANTIOXIDANTS & REDOX SIGNALING
- Nrf2-Dependent Suppression of Azoxymethane/Dextran Sulfate Sodium-Induced Colon Carcinogenesis by the Cinnamon-Derived Dietary Factor Cinnamaldehyde
- (2015) M. Long et al. Cancer Prevention Research
- Treatment With the Dipeptidyl Peptidase-4 Inhibitor Linagliptin or Placebo Followed by Glimepiride in Patients With Type 2 Diabetes With Moderate to Severe Renal Impairment: A 52-Week, Randomized, Double-Blind Clinical Trial: Figure 1
- (2015) Markku Laakso et al. DIABETES CARE
- Efficacy and tolerability of saxagliptin compared with glimepiride in elderly patients with type 2 diabetes: a randomized, controlled study (GENERATION)
- (2015) G. Schernthaner et al. DIABETES OBESITY & METABOLISM
- Efficacy and Tolerability of Sitagliptin Compared with Glimepiride in Elderly Patients with Type 2 Diabetes Mellitus and Inadequate Glycemic Control: A Randomized, Double-Blind, Non-Inferiority Trial
- (2015) Paul Hartley et al. DRUGS & AGING
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY – CLINICAL PRACTICE GUIDELINES FOR DEVELOPING A DIABETES MELLITUS COMPREHENSIVE CARE PLAN – 2015
- (2015) Yehuda Handelsman et al. Endocrine Practice
- Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: a multicentre, randomised, double-blind trial
- (2015) Faiez Zannad et al. LANCET
- Oxidative stress inhibits distant metastasis by human melanoma cells
- (2015) Elena Piskounova et al. NATURE
- Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy
- (2015) Rosa Barreira da Silva et al. NATURE IMMUNOLOGY
- Antioxidants can increase melanoma metastasis in mice
- (2015) Kristell Le Gal et al. Science Translational Medicine
- Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
- (2014) Benjamin M. Scirica et al. CIRCULATION
- Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study
- (2014) Lawrence A. Leiter et al. DIABETES CARE
- HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin
- (2014) Bo Ahrén et al. DIABETES CARE
- Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
- (2014) Michael Nauck et al. DIABETES CARE
- Dose-finding results in an adaptive, seamless, randomized trial of once-weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD-5)
- (2014) Z. Skrivanek et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone
- (2014) T. Forst et al. DIABETES OBESITY & METABOLISM
- Linagliptin improved glycaemic control without weight gain or hypoglycaemia in patients with Type 2 diabetes inadequately controlled by a combination of metformin and pioglitazone: a 24-week randomized, double-blind study
- (2014) M. Bajaj et al. DIABETIC MEDICINE
- Dual inhibition of cyclooxygenase-2 and soluble epoxide hydrolase synergistically suppresses primary tumor growth and metastasis
- (2014) G. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Kaposi's Sarcoma-Associated Herpesvirus Induces Nrf2 during De Novo Infection of Endothelial Cells to Create a Microenvironment Conducive to Infection
- (2014) Olsi Gjyshi et al. PLoS Pathogens
- Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy
- (2014) Toshihisa Ishikawa Frontiers in Genetics
- Efficacy and Safety of Sitagliptin in Patients With Type 2 Diabetes and ESRD Receiving Dialysis: A 54-Week Randomized Trial
- (2013) Juan C. Arjona Ferreira et al. AMERICAN JOURNAL OF KIDNEY DISEASES
- Tanshinone I Activates the Nrf2-Dependent Antioxidant Response and Protects Against As(III)-Induced Lung Inflammation In Vitro and In Vivo
- (2013) Shasha Tao et al. ANTIOXIDANTS & REDOX SIGNALING
- α-Lipoic acid-induced inhibition of proliferation and met phosphorylation in human non-small cell lung cancer cells
- (2013) Hiromitsu Michikoshi et al. CANCER LETTERS
- Saxagliptin Add-on Therapy to Insulin With or Without Metformin for Type 2 Diabetes Mellitus: 52-Week Safety and Efficacy
- (2013) Anthony H. Barnett et al. CLINICAL DRUG INVESTIGATION
- Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study
- (2013) Kaj Stenlöf et al. CURRENT MEDICAL RESEARCH AND OPINION
- Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin: An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
- (2013) E. Ferrannini et al. DIABETES CARE
- Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study
- (2013) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Dipeptidyl peptidase-4 inhibitors and pancreatitis risk: a meta-analysis of randomized clinical trials
- (2013) M. Monami et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
- (2013) F. J. Lavalle-González et al. DIABETOLOGIA
- The emerging role of the Nrf2-Keap1 signaling pathway in cancer
- (2013) M. C. Jaramillo et al. GENES & DEVELOPMENT
- Knockdown of Nrf2 suppresses glioblastoma angiogenesis by inhibiting hypoxia-induced activation of HIF-1α
- (2013) Xiangjun Ji et al. INTERNATIONAL JOURNAL OF CANCER
- Saxagliptin vs. glipizide as add-on therapy in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: long-term (52-week) extension of a 52-week randomised controlled trial
- (2013) Burkhard Göke et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Linagliptin for patients aged 70 years or older with type 2 diabetes inadequately controlled with common antidiabetes treatments: a randomised, double-blind, placebo-controlled trial
- (2013) Anthony H Barnett et al. LANCET
- The HMGB1/RAGE inflammatory pathway promotes pancreatic tumor growth by regulating mitochondrial bioenergetics
- (2013) R Kang et al. ONCOGENE
- APRIL Induces Tumorigenesis and Metastasis of Colorectal Cancer Cells via Activation of the PI3K/Akt Pathway
- (2013) Guihua Wang et al. PLoS One
- Diabetes treatments and cancer risk: the importance of considering aspects of drug exposure
- (2013) Jeremy J Walker et al. Lancet Diabetes & Endocrinology
- Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial
- (2013) Michael Roden et al. Lancet Diabetes & Endocrinology
- Endothelial Cell HIF-1α and HIF-2α Differentially Regulate Metastatic Success
- (2012) Cristina Branco-Price et al. CANCER CELL
- Metformin Use Is Associated with Better Survival of Diabetic Patients with Pancreatic Cancer
- (2012) N. Sadeghi et al. CLINICAL CANCER RESEARCH
- Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study
- (2012) Michel P. Hermans et al. CURRENT MEDICAL RESEARCH AND OPINION
- PKD Controls αvβ3 Integrin Recycling and Tumor Cell Invasive Migration through Its Substrate Rabaptin-5
- (2012) Claudine Christoforides et al. DEVELOPMENTAL CELL
- Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency
- (2012) J. C. Arjona Ferreira et al. DIABETES CARE
- Initial combination of linagliptin and metformin improves glycaemic control in type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2012) T. Haak et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin added to ongoing metformin and pioglitazone combination therapy in a randomized, placebo-controlled, 26-week trial in patients with type 2 diabetes
- (2012) Vivian Fonseca et al. JOURNAL OF DIABETES AND ITS COMPLICATIONS
- Inhibition of Breast Cancer Metastases by a Novel Inhibitor of TGFβ Receptor 1
- (2012) Yuanzhang Fang et al. JNCI-Journal of the National Cancer Institute
- Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial
- (2012) Pablo Aschner et al. LANCET
- 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial
- (2012) Baptist Gallwitz et al. LANCET
- Osteopontin increases heme oxygenase–1 expression and subsequently induces cell migration and invasion in glioma cells
- (2012) Dah-Yuu Lu et al. NEURO-ONCOLOGY
- Nrf2 is controlled by two distinct β-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity
- (2012) S Chowdhry et al. ONCOGENE
- The efficacy and safety of the dipeptidyl peptidase-4 inhibitor saxagliptin in treatment-naive patients with type 2 diabetes mellitus: a randomized controlled trial
- (2012) Robert Frederich et al. Diabetology & Metabolic Syndrome
- The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes*†
- (2012) Wenying YANG et al. Journal of Diabetes
- Efficacy and safety of sitagliptin added to ongoing metformin and rosiglitazone combination therapy in a randomized placebo-controlled 54-week trial in patients with type 2 diabetes (一项为期54周的对持续使用二甲双胍与罗格列酮联合治疗的2型糖尿病患者加用西格列汀治疗的有效性与安全性的随机安慰剂对照研究)*
- (2012) Adrian S. DOBS et al. Journal of Diabetes
- Efficacy and Safety of Taspoglutide Versus Sitagliptin for Type 2 Diabetes Mellitus (T-Emerge 4 Trial)
- (2012) Richard M. Bergenstal et al. Diabetes Therapy
- Drug-Induced Generalized Skin Eruption in a Diabetes Mellitus Patient Receiving a Dipeptidyl Peptidase-4 Inhibitor Plus Metformin
- (2012) Kaori Nakatani et al. Diabetes Therapy
- NRF2 Blockade Suppresses Colon Tumor Angiogenesis by Inhibiting Hypoxia-Induced Activation of HIF-1
- (2011) T.-H. Kim et al. CANCER RESEARCH
- Lactate: A Metabolic Key Player in Cancer
- (2011) F. Hirschhaeuser et al. CANCER RESEARCH
- Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
- (2011) Nir Barzilai et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and safety of alogliptin in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, dose-ranging comparison with placebo, followed by a long-term extension study
- (2011) Yutaka Seino et al. CURRENT MEDICAL RESEARCH AND OPINION
- Therapeutic Potential of Nrf2 Activators in Streptozotocin-Induced Diabetic Nephropathy
- (2011) Hongting Zheng et al. DIABETES
- Safety and efficacy of saxagliptin in combination with submaximal sulphonylurea versus up-titrated sulphonylurea over 76 weeks
- (2011) Antonio R Chacra et al. Diabetes & Vascular Disease Research
- Safety and efficacy of saxagliptin added to thiazolidinedione over 76 weeks in patients with type 2 diabetes mellitus
- (2011) Priscilla L Hollander et al. Diabetes & Vascular Disease Research
- Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study
- (2011) J. D. Lewis et al. DIABETES CARE
- Assessing the Association of Pioglitazone Use and Bladder Cancer Through Drug Adverse Event Reporting
- (2011) C. Piccinni et al. DIABETES CARE
- Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4): A 26-week double-blind study
- (2011) D. Russell-Jones et al. DIABETES CARE
- A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents
- (2011) L. Olansky et al. DIABETES OBESITY & METABOLISM
- Alogliptin as a third oral antidiabetic drug in patients with type 2 diabetes and inadequate glycaemic control on metformin and pioglitazone: a 52-week, randomized, double-blind, active-controlled, parallel-group study
- (2011) E. Bosi et al. DIABETES OBESITY & METABOLISM
- Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes
- (2011) J. Wainstein et al. DIABETES OBESITY & METABOLISM
- Sitagliptin more effectively achieves a composite endpoint for A1C reduction, lack of hypoglycemia and no body weight gain compared with glipizide
- (2011) Thomas L. Seck et al. DIABETES RESEARCH AND CLINICAL PRACTICE
- One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
- (2011) R. Pratley et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Long-term treatment with the dipeptidyl peptidase-4 inhibitor saxagliptin in patients with type 2 diabetes mellitus and renal impairment: a randomised controlled 52-week efficacy and safety study
- (2011) M. Nowicki et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
- Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
- (2011) Gina M. DeNicola et al. NATURE
- Effects of vildagliptin on postprandial markers of bone resorption and calcium homeostasis in recently diagnosed, well-controlled type 2 diabetes patients*
- (2011) Mathijs C. BUNCK et al. Journal of Diabetes
- Diabetes and Cancer: A Consensus Report
- (2010) E. Giovannucci et al. CA-A CANCER JOURNAL FOR CLINICIANS
- High Levels of Nrf2 Determine Chemoresistance in Type II Endometrial Cancer
- (2010) T. Jiang et al. CANCER RESEARCH
- Oxidative Stress in Diabetic Nephropathy
- (2010) N. Kashihara et al. CURRENT MEDICINAL CHEMISTRY
- Genetic Deletion or Pharmacological Inhibition of Dipeptidyl Peptidase-4 Improves Cardiovascular Outcomes After Myocardial Infarction in Mice
- (2010) M. Sauve et al. DIABETES
- Initial Combination Therapy With Alogliptin and Pioglitazone in Drug-Naive Patients With Type 2 Diabetes
- (2010) J. Rosenstock et al. DIABETES CARE
- Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients
- (2010) E. Mannucci et al. DIABETES CARE
- Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial
- (2010) R. Arechavaleta et al. DIABETES OBESITY & METABOLISM
- Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial
- (2010) S. Del Prato et al. DIABETES OBESITY & METABOLISM
- The Critical Role of Nitric Oxide Signaling, via ProteinS-Guanylation and Nitrated Cyclic GMP, in the Antioxidant Adaptive Response
- (2010) Shigemoto Fujii et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial
- (2010) Richard M Bergenstal et al. LANCET
- Keap1 perceives stress via three sensors for the endogenous signaling molecules nitric oxide, zinc, and alkenals
- (2010) M. McMahon et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
- (2009) Richard E. Pratley et al. CURRENT MEDICAL RESEARCH AND OPINION
- Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes
- (2009) J. Rosenstock et al. CURRENT MEDICAL RESEARCH AND OPINION
- Additive Interaction Between the Renin-Angiotensin System and Lipid Metabolism for Cancer in Type 2 Diabetes
- (2009) X. Yang et al. DIABETES
- The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone
- (2009) R. A. DeFronzo et al. DIABETES CARE
- Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA1cwithout causing weight gain or increased hypoglycaemia
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial
- (2009) M. Jadzinsky et al. DIABETES OBESITY & METABOLISM
- Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus
- (2009) J. Rosenstock et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
- (2009) R. E. Pratley et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
- (2009) P. Aschner et al. DIABETES OBESITY & METABOLISM
- Efficacy and safety of sitagliptin when added to insulin therapy in patients with type 2 diabetes
- (2009) T. Vilsbøll et al. DIABETES OBESITY & METABOLISM
- Does diabetes therapy influence the risk of cancer?
- (2009) U. Smith et al. DIABETOLOGIA
- A Colorectal Cancer Expression Profile That Includes Transforming Growth Factor β Inhibitor BAMBI Predicts Metastatic Potential
- (2009) Johannes Fritzmann et al. GASTROENTEROLOGY
- Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes
- (2008) Itamar Raz et al. CURRENT MEDICAL RESEARCH AND OPINION
- Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Alogliptin in Patients With Type 2 Diabetes and Inadequate Glycemic Control: A randomized, double-blind, placebo-controlled study
- (2008) R. A. DeFronzo et al. DIABETES CARE
- Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea*
- (2008) A. J. Garber et al. DIABETES OBESITY & METABOLISM
- Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency
- (2008) J. C. N. Chan et al. DIABETES OBESITY & METABOLISM
- Efficacy and Safety of Vildagliptin Monotherapy during 2-Year Treatment of Drug-naïve Patients with Type 2 Diabetes: Comparison with Metformin
- (2008) B. Göke et al. HORMONE AND METABOLIC RESEARCH
- Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study
- (2008) M. A. Nauck et al. INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More